Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1643 1645 1672 1674 1699 1793
This examiner grants 64% of resolved cases
Examiner Cheom-Gil Cheong operates within Tech Center 1700 and Art Unit 1643, where they have managed 190 resolved cases. The data shows an allowance rate of 64.2%, which provides a baseline for expectations during prosecution. A notable metric for practitioners is the interview lift of 52.6%, suggesting that personal engagement with this examiner may improve the probability of an allowance compared to the 64.2% baseline. This lift indicates that interviews are a productive tool for moving toward a grant in this specific queue.
The timeline for reaching a final disposition is also a factor, as the median days to allowance stands at 1215. This duration reflects the typical path for successful applications in this examiner's portfolio. Given the interview lift of 52.6%, attorneys might prioritize early interviews to navigate the 1215 days of pendency. With 190 resolved cases, the examiner has established a consistent pattern of behavior in Art Unit 1643. Practitioners should prepare for a prosecution cycle that typically lasts 1215 days while leveraging the 64.2% allowance rate to their advantage.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | Final Rejection | Quest Diagnostics Investments LLC |
| 16771510 | Inducible Cell Receptors for Cell-Based Therapeutics | Non-Final OA | Trustees of Boston University |
| 16979209 | COMPOSITIONS AND METHODS FOR DETECTING MYCOBACTERIUM TUBERCULOSIS | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18683538 | POSTBIOTIC | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18623995 | REGULATOR OF TUMOR CELL FUNCTIONS AND USES THEREOF | Non-Final OA | Washington University |
| 18429870 | Cutibacterium Acnes Biomimetic, Prebiotic, Probiotic and Postbiotic Compositions for Treatment of Skin Conditions | Non-Final OA | Johnson & Johnson Consumer Inc. |
| 18692937 | METHODS FOR TREATING NEUROINFLAMMATION | Non-Final OA | University of Virginia Patent Foundation |
| 18672417 | POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18150466 | ALTERNATIVE SURFACTANTS AS STABILIZERS FOR THERAPEUTIC PROTEIN FORMULATIONS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18189874 | METHODS, DEVICE, KIT AND COMPOSITIONS FOR DETECTING FELINE LUNGWORM | Non-Final OA | Idexx Laboratories, Inc. |
| 18704632 | MALARIA VACCINE FORMULATIONS | Non-Final OA | NOVAVAX, INC. |
| 16823313 | INSECT PRODUCTION SYSTEMS AND METHODS | Final Rejection | INSECTERGY, LLC |
| 18564618 | INDICATOR MOLECULE FOR TOXIGENICITY OF AFLATOXIGENIC FUNGI AND USE THEREOF | Final Rejection | OIL CROPS RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy